IL270153A - - Google Patents

Info

Publication number
IL270153A
IL270153A IL27015319A IL27015319A IL270153A IL 270153 A IL270153 A IL 270153A IL 27015319 A IL27015319 A IL 27015319A IL 27015319 A IL27015319 A IL 27015319A IL 270153 A IL270153 A IL 270153A
Authority
IL
Israel
Application number
IL27015319A
Other languages
English (en)
Other versions
IL270153B2 (en
IL270153B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL270153A publication Critical patent/IL270153A/en
Publication of IL270153B1 publication Critical patent/IL270153B1/en
Publication of IL270153B2 publication Critical patent/IL270153B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL270153A 2017-04-27 2018-04-27 Antitumoral compounds IL270153B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26
PCT/EP2018/060868 WO2018197663A1 (en) 2017-04-27 2018-04-27 Antitumoral compounds

Publications (3)

Publication Number Publication Date
IL270153A true IL270153A (https=) 2019-12-31
IL270153B1 IL270153B1 (en) 2023-06-01
IL270153B2 IL270153B2 (en) 2023-10-01

Family

ID=62063080

Family Applications (3)

Application Number Title Priority Date Filing Date
IL295044A IL295044B2 (en) 2017-04-27 2018-04-27 Antitumor compounds
IL270153A IL270153B2 (en) 2017-04-27 2018-04-27 Antitumoral compounds
IL289963A IL289963B2 (en) 2017-04-27 2018-04-27 Antitumor compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL295044A IL295044B2 (en) 2017-04-27 2018-04-27 Antitumor compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL289963A IL289963B2 (en) 2017-04-27 2018-04-27 Antitumor compounds

Country Status (39)

Country Link
US (5) US11332480B2 (https=)
EP (5) EP4101855B9 (https=)
JP (5) JP7186723B2 (https=)
KR (3) KR102510975B1 (https=)
CN (4) CN114751920B (https=)
AU (4) AU2018260314C1 (https=)
BR (1) BR112019022282A2 (https=)
CA (2) CA3298833A1 (https=)
CL (1) CL2019003057A1 (https=)
CO (1) CO2019011967A2 (https=)
CY (3) CY1121885T1 (https=)
DK (5) DK3395821T3 (https=)
EC (1) ECSP19083967A (https=)
ES (5) ES2944344T3 (https=)
FI (3) FI4101855T3 (https=)
HK (2) HK1255938B (https=)
HR (5) HRP20231233T1 (https=)
HU (5) HUE062157T2 (https=)
IL (3) IL295044B2 (https=)
JO (1) JOP20190254B1 (https=)
LT (5) LT3395820T (https=)
MA (2) MA44020B1 (https=)
MD (5) MD3395821T2 (https=)
ME (2) ME03466B (https=)
MX (3) MX392829B (https=)
MY (1) MY198004A (https=)
PH (1) PH12019550224A1 (https=)
PL (5) PL3615544T3 (https=)
PT (2) PT3395820T (https=)
RS (5) RS59174B1 (https=)
SA (1) SA523440283B1 (https=)
SG (2) SG11201909841RA (https=)
SI (5) SI3395821T1 (https=)
SM (5) SMT201900447T1 (https=)
TN (2) TN2019000211A1 (https=)
TW (3) TWI875118B (https=)
UY (1) UY37706A (https=)
WO (1) WO2018197663A1 (https=)
ZA (1) ZA201907119B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
JP2023503318A (ja) * 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法
KR20230004714A (ko) * 2020-04-21 2023-01-06 파르마 마르, 에스.에이. 약물 항체 접합체
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
TW202313039A (zh) 2021-05-19 2023-04-01 西班牙商瑪製藥股份有限公司 Pm14用途與方案
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP4563149A1 (en) 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
WO2025228596A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer
TW202547488A (zh) 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 於癌症的治療中之化合物Ia和拓樸異構酶I抑制劑的組合
WO2025228595A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
WO2025228594A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab
WO2025233522A1 (en) 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin
WO2026022359A2 (en) 2024-07-26 2026-01-29 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
HU201672B (en) 1984-12-28 1990-12-28 Conpharm Ab Process for producing pharmaceutical compositions comprising podophyllotoxin
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
ATE74761T1 (de) 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン729、743、745、759a、759bおよび770
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
DE68903907T2 (de) 1988-09-05 1993-06-09 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
WO1990005731A1 (en) 1988-11-24 1990-05-31 University Of Queensland Cytotoxic macromolecules
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質S−59917a及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
WO1994004541A2 (en) 1992-08-12 1994-03-03 The Upjohn Company Protein kinase inhibitors and related compounds combined with taxol
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
PT956033E (pt) 1996-10-24 2003-10-31 Univ Illinois SíNTESE TOTAL DE ANALOGOS AMINO HIP DE DIDEMNINA A
DE69735583T2 (de) 1996-10-24 2007-04-05 The Board Of Trustees Of The University Of Illinois, Urbana Semisynthetisches verfahren zur herstellung von didemninanalogen
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
EP0981352B8 (en) 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CN1157189C (zh) 1998-04-06 2004-07-14 伊利诺伊大学评议会 半合成海鞘素
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
EP1076486B1 (en) 1998-05-05 2005-08-31 Pharma Mar, S.A. Culture of sessile marine animals
EP1077698B1 (en) * 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
CN1423564A (zh) 1999-11-15 2003-06-11 法马马有限公司 癌症的aplidine治疗
JP2003520801A (ja) 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US6864283B2 (en) 2000-02-16 2005-03-08 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
JP5219323B2 (ja) 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
EP1287006B1 (en) 2000-06-06 2007-10-24 Pharma Mar, S.A. Antitumoral compounds
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
WO2002004447A1 (en) 2000-07-11 2002-01-17 Pharma Mar, S.A. Variolin derivatives as anti-cancer agents
EP1299035B1 (en) 2000-07-13 2013-02-13 ReCor Medical, Inc. Thermal treatment apparatus with focussed energy application
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
CZ2003993A3 (cs) 2000-10-12 2004-02-18 Pharma Mar, S. A. Léčivo pro léčení rakoviny podáváním aplidinu nebo analogu aplidinu a protektoru kosterního svalstva
AU9402401A (en) 2000-10-12 2002-04-22 Pharma Mar Sa Treatment of cancers
ES2256305T3 (es) 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
EP1365808B1 (en) 2000-11-06 2011-01-19 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
JP2004521112A (ja) 2001-01-24 2004-07-15 メステックス アクチエンゲゼルシャフト 関節痛治療薬を製造することへの神経毒性物質の使用
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
WO2003033012A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
WO2003033013A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
BR0213424A (pt) 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
NZ539093A (en) 2002-10-18 2007-10-26 Pharma Mar Sau 4-methylhexanoic kahalaide F compound
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
ATE406171T1 (de) 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
CA2519234A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
CN1856486A (zh) 2003-07-25 2006-11-01 诺瓦提斯公司 取代的内酰胺和它们作为抗癌剂的用途
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
EP1680415B1 (en) 2003-10-09 2008-12-31 Abbott Laboratories Pyrrolidinyl urea derivatives as angiogenesis inhibitors
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
MX2007000360A (es) 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
DK1827500T3 (da) 2004-10-26 2009-08-31 Pharma Mar Sa Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
CN101171236A (zh) 2005-05-03 2008-04-30 马尔药品公司 抗肿瘤的四氢嘧啶
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
RU2008107974A (ru) 2005-08-02 2009-09-10 Фарма Мар, С.А. (Es) Гены, участвующие в биосинтезе тиокоралина и его гетерологичном продуцировании
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
DE602006020335D1 (de) 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
CN101389347B (zh) 2006-02-28 2013-03-27 法马马有限公司 提高的抗肿瘤治疗
JP2009536956A (ja) 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
HRP20110845T1 (hr) 2006-06-16 2011-12-31 Pharma Mar Antitumorski dihidropiran-2-onski spojevi
JP2011500046A (ja) 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Et−743治療のための予後分子マーカー
WO2009052379A2 (en) 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
AU2008313627A1 (en) 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
EP2231695B1 (en) 2007-12-14 2013-02-13 Pharma Mar, S.A. Antitumoral compounds
PT2231633E (pt) 2007-12-20 2014-01-20 Pharma Mar Sa Compostos antitumorais
AU2009209541A1 (en) 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
CN101965192A (zh) 2008-03-07 2011-02-02 法马马有限公司 改善的抗肿瘤治疗
US20110009335A1 (en) 2008-03-07 2011-01-13 Pharma Mar, S.A. Anticancer Treatments
CA2724206A1 (en) 2008-05-16 2009-11-19 Pharma Mar S.A. Multiple myeloma treatments
CA2724325A1 (en) 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with an antitumor alkaloid
AP2775A (en) 2008-05-23 2013-09-30 Wyeth Llc Triazine compounds as P13 kinase and MTOR inhibitors
EP2321325A1 (en) 2008-07-03 2011-05-18 Pharma Mar S.A. Antitumoral macrolides
CN102159248B (zh) 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
CN102099370A (zh) 2008-07-17 2011-06-15 马尔药品公司 抗癌化合物
MX2011006532A (es) 2008-12-19 2011-07-13 Pharma Mar Sa Compuestos anticancerigenos.
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
PL2563803T3 (pl) 2010-04-27 2016-08-31 Pharma Mar Sa Przeciwnowotworowe laktony steroidowe nienasycone w pozycji 7(8)
CN107033164A (zh) * 2010-05-25 2017-08-11 法马马有限公司 制备海鞘素化合物的合成方法
ME02395B (me) 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
DE102012211024B4 (de) 2012-06-27 2024-10-24 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
TWI875118B (zh) 2025-03-01
CO2019011967A2 (es) 2020-02-18
IL270153B2 (en) 2023-10-01
EP4047002A1 (en) 2022-08-24
HK1255941B (en) 2020-04-29
HRP20230455T1 (hr) 2023-07-21
JP6501947B2 (ja) 2019-04-17
EP3395820B1 (en) 2019-05-15
RS64174B1 (sr) 2023-05-31
HRP20191442T1 (hr) 2019-11-15
FI4047002T3 (fi) 2023-05-22
ES2944344T3 (es) 2023-06-20
EP4101855A1 (en) 2022-12-14
ECSP19083967A (es) 2019-12-27
RS64686B1 (sr) 2023-11-30
KR102510975B1 (ko) 2023-03-16
SA523440283B1 (ar) 2025-04-26
NZ758490A (en) 2025-06-27
AU2022200249C1 (en) 2022-06-23
CN114751920A (zh) 2022-07-15
AU2022200249B1 (en) 2022-02-10
US20220242883A1 (en) 2022-08-04
US11713325B2 (en) 2023-08-01
MD4047002T2 (ro) 2023-08-31
EP3615544A1 (en) 2020-03-04
IL270153B1 (en) 2023-06-01
PL3615544T3 (pl) 2023-07-17
BR112019022282A2 (pt) 2020-05-19
CN117865987A (zh) 2024-04-12
DK3615544T3 (da) 2023-05-30
MX2019012812A (es) 2020-01-14
AU2022201657A1 (en) 2022-03-31
LT3395820T (lt) 2019-08-12
US10538535B2 (en) 2020-01-21
HUE062032T2 (hu) 2023-09-28
EP3395821B1 (en) 2019-05-15
MX392601B (es) 2025-03-24
MA44021A (fr) 2019-05-15
JP2023052597A (ja) 2023-04-11
IL295044B2 (en) 2023-11-01
JOP20190254A1 (ar) 2019-10-27
SI4101855T1 (sl) 2024-03-29
SG10201913300YA (en) 2020-03-30
JP7186723B2 (ja) 2022-12-09
SI3615544T1 (sl) 2023-07-31
SMT202300169T1 (it) 2023-07-20
SMT202300160T1 (it) 2023-07-20
PL3395821T3 (pl) 2019-10-31
AU2018260314C1 (en) 2022-04-21
PT3395820T (pt) 2019-08-07
AU2022200250B1 (en) 2022-02-10
JOP20190254B1 (ar) 2024-04-18
JP7422812B2 (ja) 2024-01-26
WO2018197663A1 (en) 2018-11-01
KR102491180B1 (ko) 2023-01-20
SMT201900447T1 (it) 2019-09-09
JP2018188432A (ja) 2018-11-29
ES2960063T3 (es) 2024-02-29
US20210070775A1 (en) 2021-03-11
ZA201907119B (en) 2021-07-28
EP4047002B1 (en) 2023-03-08
HUE045641T2 (hu) 2020-01-28
HUE063736T2 (hu) 2024-01-28
ES2741901T3 (es) 2020-02-12
NZ797532A (en) 2025-06-27
TWI742273B (zh) 2021-10-11
LT4047002T (lt) 2023-05-10
JP6501946B2 (ja) 2019-04-17
ES2944579T3 (es) 2023-06-22
HRP20191443T1 (hr) 2019-11-15
IL295044B1 (en) 2023-07-01
US11332480B2 (en) 2022-05-17
EP3395820A1 (en) 2018-10-31
EP4101855B1 (en) 2023-08-02
MX392829B (es) 2025-03-24
HRP20231233T1 (hr) 2024-01-19
KR20220109495A (ko) 2022-08-04
CN110621678B (zh) 2024-09-20
CN114751920B (zh) 2024-06-07
CN110621678A (zh) 2019-12-27
HK1255938B (en) 2020-04-29
HUE062157T2 (hu) 2023-10-28
HRP20230433T1 (hr) 2023-07-07
IL289963B1 (en) 2023-06-01
SI3395820T1 (sl) 2019-09-30
JP2022130682A (ja) 2022-09-06
KR20200012846A (ko) 2020-02-05
CN114736219A (zh) 2022-07-12
CA3298833A1 (en) 2026-03-02
TW202344509A (zh) 2023-11-16
CN114736219B (zh) 2024-06-07
MY198004A (en) 2023-07-25
US12384800B2 (en) 2025-08-12
IL289963A (en) 2022-03-01
DK3395820T3 (da) 2019-08-12
AU2018260314A1 (en) 2019-10-31
FI3615544T3 (fi) 2023-05-23
EP3615544B1 (en) 2023-03-22
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
KR102492283B1 (ko) 2023-01-27
TN2019000210A1 (en) 2021-01-07
EP4101855B9 (en) 2024-01-03
ES2740073T3 (es) 2020-02-05
DK4047002T3 (da) 2023-05-01
CY1126061T1 (el) 2023-11-15
US20240166666A1 (en) 2024-05-23
RS59173B1 (sr) 2019-10-31
RS64200B1 (sr) 2023-06-30
SMT202300343T1 (it) 2023-11-13
US20210246146A1 (en) 2021-08-12
MA44020A (fr) 2018-10-31
DK4101855T3 (da) 2023-11-06
PH12019550224A1 (en) 2020-10-12
AU2022200250C1 (en) 2022-06-23
LT4101855T (lt) 2023-08-25
ME03467B (me) 2020-01-20
JP7490835B2 (ja) 2024-05-27
RS59174B1 (sr) 2019-10-31
ME03466B (me) 2020-01-20
EP3395821A1 (en) 2018-10-31
FI4101855T3 (fi) 2023-09-22
TW201906850A (zh) 2019-02-16
CY1121885T1 (el) 2020-10-14
SMT201900448T1 (it) 2019-09-09
IL295044A (en) 2022-09-01
SI3395821T1 (sl) 2019-09-30
MA44021B1 (fr) 2019-08-30
IL289963B2 (en) 2023-10-01
SI4047002T1 (sl) 2023-07-31
CA3061518A1 (en) 2018-11-01
TWI807411B (zh) 2023-07-01
NZ797531A (en) 2025-06-27
EP3615544B9 (en) 2024-01-03
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
JP2018188431A (ja) 2018-11-29
PL4047002T3 (pl) 2023-07-24
US20180312529A1 (en) 2018-11-01
HUE046109T2 (hu) 2020-02-28
JP2020517709A (ja) 2020-06-18
AU2018260314B2 (en) 2021-12-09
LT3615544T (lt) 2023-05-10
MD3615544T2 (ro) 2023-08-31
DK3395821T3 (da) 2019-08-19
PT3395821T (pt) 2019-08-27
MX2021016054A (es) 2022-06-01
TN2019000211A1 (en) 2021-01-07
MX2021016058A (es) 2022-02-03
UY37706A (es) 2018-11-30
CL2019003057A1 (es) 2020-02-21
SG11201909841RA (en) 2019-11-28
MD3395820T2 (ro) 2019-10-31
TW202202509A (zh) 2022-01-16
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
LT3395821T (lt) 2019-08-12
KR20210126791A (ko) 2021-10-20
CY1121884T1 (el) 2020-10-14

Similar Documents

Publication Publication Date Title
BR122021024397A2 (https=)
BR122021000189A2 (https=)
BR112020006084A8 (https=)
BR122022025811B8 (https=)
BR202018014992U2 (https=)
BR122021023687A2 (https=)
BR122021014832A2 (https=)
BR122022003518A2 (https=)
BR112020008820A2 (https=)
BR202017025154U2 (https=)
BR202017021228U2 (https=)
BR202017020981U2 (https=)
BE2017C035I2 (https=)
BR202017017068U2 (https=)
BR202017016984U2 (https=)
BR202017016924U2 (https=)
BR102017014430A2 (https=)
BR202017012548U2 (https=)
BR202017011220U2 (https=)
BR202017010814U2 (https=)
BR202017010373U2 (https=)
BR202017009870U2 (https=)
BR202017006953U2 (https=)
BR202017004898U2 (https=)
BR102017003115A2 (https=)